Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients

Annalisa Saracino, Laura Monno, Alessandra Tartaglia, Carmine Tinelli, Elena Seminari, Franco Maggiolo, Stefano Bonora, Stefano Rusconi, Valeria Micheli, Sergio Lo Caputo, Laura Lazzaroni, Sergio Ferrara, Nicoletta Ladisa, Paola Nasta, Giustino Parruti, Rita Bellagamba, Federica Forbici, Gioacchino Angarano

Research output: Contribution to journalArticlepeer-review

Abstract

Tipranavir, a non-peptidic protease inhibitor which shows in vitro efficacy against some HIV-1-resistant strains, can be used in salvage therapies for multi-experienced HIV patients due to its peculiar resistance profile including 21 mutations at 16 protease positions according to International AIDS Society (IAS). Other genotypic scores, however, which attribute a different weight to single amino-acid substitutions, have been recently proposed. To validate the clinical utility of four different genotypic scores for selecting tipranavir responders, the baseline resistance pattern of 176 HIV heavily experienced patients was correlated with virological success (HIV-RNA

Original languageEnglish
Pages (from-to)425-433
Number of pages9
JournalCurrent HIV Research
Volume7
Issue number4
DOIs
Publication statusPublished - Jul 2009

Keywords

  • Antiretrovirals
  • Genotypic resistance
  • Protease inhibitors
  • Tipranavir

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Fingerprint Dive into the research topics of 'Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients'. Together they form a unique fingerprint.

Cite this